Table 1.
Patient characteristics
| UMMC (%) | VAMHCS (%) | Total (%) | |
|---|---|---|---|
| Total n | 12 | 16 | 28 |
| Median age (years, IQR) | 39.5 | 59.5 | 52 (21.5) |
| Male | 10 (83) | 16 (100) | 26 (93) |
| Comorbidities | |||
| Substance abuse | 9 (75) | 10 (63) | 19 (68) |
| DM | 0 (0) | 6 (40) | 6 (21) |
| Hepatitis C | 4 (33) | 3 (19) | 7 (25) |
| Vascular | 0 (0) | 4 (25) | 4 (14) |
| Cardiovascular | 1 (8) | 3 (19) | 4 (14) |
| Malignancy | 1 (8) | 1 (6) | 2 (7) |
| CKD | 0 (0) | 2 (13) | 2 (7) |
| HIV | 0 (0) | 1 (6) | 1 (4) |
| Infection | |||
| Osteomyelitis | 3 (25) | 10 (63) | 13 (46) |
| Endovascular | 4 (33) | 2 (13) | 6 (21) |
| Bacteremia | 3 (25) | 1 (6) | 4 (14) |
| Othera | 2 (17) | 3 (19) | 5 (18) |
| Culture | |||
| MRSA | 6 (50) | 2 (13) | 8 (29) |
| MSSA | 3 (25) | 3 (19) | 6 (21) |
| CoNS | 1 (8) | 3 (19) | 4 (14) |
| Mixed GPO | 0 (0) | 8 (50) | 8 (29) |
| Not available | 2 (17) | 3 (19) | 5 (18) |
| Reason for dalbavancin | |||
| PWID | 9 (75) | 7 (44) | 16 (57) |
| Patient refusal of PICC | 2 (17) | 2 (13) | 4 (14) |
| Otherb | 1 (8) | 5 (31) | 6 (21) |
| Substance usec | 0 (0) | 2 (13) | 2 (7) |
| Location of initiation of dalbavancin | |||
| Inpatient | 11 (92) | 11 (69) | 22 (79) |
| Outpatient | 1 (8) | 5 (33) | 6 (21) |
| Median dalbavancin doses (IQR) | 1.5 | 5.5 | 3 (4.5) |
| Median LOPA (days, IQR) | 9 | 15 | 13.5 (16) |
| Median LOS (days, IQR) | 10 | 7 | 8 (12.5) |
VAMHCS VA Maryland Health Care System, UMMC University of Maryland Medical Center, DM diabetes mellitus, HIV human immunodeficiency virus, CKD chronic kidney disease, MSSA methicillin susceptible S. aureus, MRSA methicillin-resistant S. aureus, CoNS coagulase-negative staphylococcus, GPO gram-positive organisms, PWID persons who inject drugs, LOPA length of prior antibiotic, LOS length of stay
aMRSA pneumonia, septic arthritis, prosthetic joint infection, cardiac device infection, pyelonephritis
bLack of home support, homelessness, not documented
cNon-injectable substance